COVID-19

Eschbach: better communication boosts pharma manufacturing

21-Sep-2020 By Jenni Spinner

A leader from the pharma software solutions provider suggests streamlining communication between shifts can avoid manufacturing snags.

Phesi: COVID-19 fueling trial suspensions

21-Sep-2020 By Jenni Spinner

A recent study from the clinical research services firm indicates the pandemic continues to significantly impact clinical trial sites around the globe.

Deloitte survey reveals pharma CEO thoughts

21-Sep-2020 By Jenni Spinner

The latest iteration of the company’s Pharma CEO Survey offers information and insight as to how key industry figures are planning for the future.

CTI acquires CRO based in Middle East, Africa

17-Sep-2020 By Jenni Spinner

CTI Clinical Trial and Consulting Services has expanded its global reach by purchasing Clinart, a full-service CRO with precence in the MENA region.

Latest COVID-19 news from the FDA

17-Sep-2020 By Jenni Spinner

The US agency continues to issue advice for life-sciences professionals engaged in work related to the virus, and keep an eye out for fraudulent products.

CPhI shifts from real-world to digital realm

16-Sep-2020 By Jenni Spinner

In the face of the COVID-19 pandemic, CPhI Festival of Pharma organizers have shifted the event online but kept the industry content.

Platform forecasts COVID-19 trial outcomes

15-Sep-2020 By Jenni Spinner

The technology from Opyl uses artificial intelligence to anticipate a COVID-19 treatment, vaccine, diagnostic or device’s chances of success in a study.

Medable: COVID-19 fueling decentralized trial adoption

10-Sep-2020 By Jenni Spinner

The company credits its 400% year-over-year growth to rapid acceleration in adoption of virtual clinical trial technology, due in part to the vlrus.

Cynata Therapeutics kicks off COVID-19 trial enrollment

09-Sep-2020 By Jenni Spinner

The clinical-stage biotech firm is investigating early efficacy of its Cymerus mesenchymal stem cells for treatment of severe COVID-19 patients.

JanOne poised to produce drug for CV, COVID-19 trials

08-Sep-2020 By Jenni Spinner

Partnering with Eurofins, the company has verified the developmental batch of its JAN101, aimed to treat cardiovascular conditions and COVID-19.

FSD Pharma announces Phase II trial for potential COVID-19 treatment

08-Sep-2020 By Jenni Spinner

The company has submitted an investigational new drug application for FSD201, a possible therapy for patients with severe cases of the virus.

COVID-19 treatment study predicts adverse drug events

03-Sep-2020 By Jenni Spinner

Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.

COVID-19 report shares insights on potential therapies

01-Sep-2020 By Jenni Spinner

A new scientific report offers a comprehensive review of protein targets, associated COVID-19 drug candidates to date and other revealing information.

NIAID awards $44m contract to advance COVID-19 drug

31-Aug-2020 By Jenni Spinner

The US institute has given a new contract to drug developer BioCryst to explore use of galidesivir in treatment of non-hospitalized COVID-19 patients.